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Background: Detection of early vascular changes prior to clinical manifestations of atherosclerosis, such as
increased arterial carotid intima-media thickness (CIMT) and impaired endothelial function is of paramount
importance for early identification of subjects at increased risk of accelerated atherosclerosis. The present study was
designed to evaluate the relationship between early atherosclerosis and endothelial dysfunction in type 1 diabetic
patients based on measurements of CIMT and soluble CD146 (sCD146) levels.
Methods: Thirty-seven patients with type 1 diabetes, 14 males (37.8%) and 23 females (62.2%), of mean (SD) age
26.2 (4.1) years admitted to the outpatient diabetes clinic at Okmeydani Training and Research Hospital, Istanbul,
between January 2008 and December 2012, and 37 healthy controls, 16 males (43.2%) and 21 females (56.8%), of
mean (SD) age 25.8 (3.1) years, selected from relatives of patients, were included. Anthropometric measures; fasting
plasma glucose; and serum HbA1c, total cholesterol, HDL-cholesterol, LDL-cholesterol, triglyceride and creatinine
concentrations were compared, as were CIMT and serum sCD146.
Results: Mean (SD) sCD146 levels were significantly higher in patients than in controls (314.6 (141.9) ng/ml vs. 207.8
(34.5) ng/ml, p = 0.001), but mean (SD) CIMT did not differ (0.5 (0.1) mm vs. 0.4 (0.1) mm). ROC curves for sCD146
significantly differed in differentiating type 1 diabetics from healthy controls (p = 0.0047) with a significantly higher
percentage of patients than controls having sCD146 levels >260 ng/ml (21/37 (56.8%) vs. 2/37 (5.4%),
p = 0.00011).
Conclusion: Our findings emphasize that sCD146 levels may be a more sensitive marker than CIMT for earlier
identification of type 1 diabetic patients at high risk for atherosclerosis.
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Atherosclerosis is an important macrovascular complica-
tion and the major cause of morbidity and mortality in
patients with diabetes mellitus [1]. Moreover, diabetes
mellitus itself is a risk factor for atherosclerosis [2]. Al-
though type 1 diabetics are at lower risk for atheroscler-
otic cardiovascular disease than type 2 diabetics due to
the younger age of the former group the relative risk is
10 times higher in type 1 diabetics than in non-diabetics
of similar age [3-5]. In addition, type 1 diabetes has been
associated with increased intima media thickness and
decreased endothelial function even in childhood [6], em-
phasizing the importance of early detection and prevention
of macrovascular disease in patients with juvenile-onset
type 1 diabetes.
Owing to its central role in vascular homeostasis,
endothelial function and endothelial cells themselves
may play a key role in vascular diseases related to ath-
erosclerosis [7]. In addition, endothelial dysfunction has
been considered the critical mechanism underlying the
atherosclerotic pathogenesis of diabetes [8]. Measuring
biological markers of vascular endothelial function in vivo
may therefore provide insights into the evolution and
prognosis of vascular diseases [7]. For example, although
circulating endothelial cells (CECs) expressing the mem-
brane glycoprotein CD146 are rarely found in the blood of
healthy subjects, their release from damaged endothelium
in individuals with cardiovascular and inflammatory dis-
eases leads to increased levels of CD146 in the peripheral
circulation [7,9].
Although there is no standardized method for detecting
CECs, measurement of soluble CD146 (sCD146) has be-
come the most commonly used specific marker for the de-
tection of CECs in peripheral blood [10]. sCD146, also
known as S-Endo 1-associated antigen, MelCAM and
MUC, is located at intercellular margins and therefore is
likely to act as an adhesion molecule [10-12].
Another established clinical index of vascular endothe-
lial function closely related to atherosclerosis is carotid
intima-media thickness (CIMT) [13]. Measurements of
CIMT have been considered relatively simple and cost-
effective, as well as being a surrogate marker for subclinical
atherosclerosis [14].
The detection of early vascular changes prior to the clin-
ical manifestations of atherosclerosis, such as increased
CIMT and impaired endothelial function, are of para-
mount importance for the early identification of subjects
at increased risk of accelerated atherosclerosis [15,16].
However, although both parameters are commonly mea-
sured in clinical trials, no consensus has yet been reached
on the superiority and/or priority of morphological vs.
endothelial alterations in subjects at increased risk for ath-
erosclerosis [16]. Furthermore, although several studies have
reported that CIMT can predict subclinical atherosclerosisin diabetic patients [17-22], less is known on whether CECs
can act as a marker of endothelial cell activation and dam-
age in diabetic individuals [23-27].
This study was therefore designed to evaluate sCD146
levels and CIMT as early predictors of endothelial dam-
age and atherosclerosis, respectively, in type 1 diabe-
tic patients without diabetes-related complications or
additional cardiovascular risk factors and to compare
CIMT and sCD146 levels in type 1 diabetics and
healthy controls.Methods
Study population
Thirty-seven patients with type 1 diabetes, 14 males
(37.8%) and 23 females (62.2%), of mean (SD) age 26.2
(4.1) years admitted to the outpatient diabetes clinic at
Okmeydani Training and Research Hospital, Istanbul, be-
tween January 2008 and December 2012, and 37 healthy
controls, 16 males (43.2%) and 21 females (56.8%), of
mean (SD) age 25.8 (3.1) years, selected from relatives of
patients, were included. Patients were included if they
were aged 20–40 years, had type 1 diabetes for at least
one year, were receiving only insulin as anti-diabetic treat-
ment, and lacked diabetes related complications and add-
itional cardiovascular risk factors. Controls were included
if they were aged ≥20 years and had normal fasting blood
glucose concentrations. Individuals were excluded if they
had any systemic disease known to cause endothelial dys-
function, including systemic hypertension (defined accor-
ding to the JNC-7 criteria) [28], hyperlipidemia (defined
according to the NCEP-ATP3 criteria) [29], coronary ar-
tery disease, peripheral vascular disease, retinopathy, neur-
opathy, carotid artery disease, inflammatory or infectious
processes within the last 3 months, or malignancy. Indi-
viduals were also excluded if they had a body mass index
(BMI) >25 kg/m2, had undergone any invasive procedure
in the month before enrollment, had abnormal renal
(including micro-albuminuria) or hepatic biochemical
markers, were receiving any medication affecting endothe-
lial function, or were active smokers. Written informed
consent was obtained from each subject following a de-
tailed explanation of the objectives and protocol of the
study, which was conducted in accordance with the ethical
principles, stated in the “Declaration of Helsinki” and was
approved by the Okmeydani Training and Research Hos-
pital Ethics Committee.Assessments
Anthropometric measures, fasting plasma glucose and
HbA1c concentrations, and serum total cholesterol,
HDL-cholesterol, LDL-cholesterol, triglyceride, creatin-
ine, and sCD146 levels were measured, as was CIMT.
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Blood samples were collected in tubes containing EDTA
and centrifuged at 3000 rpm at 4°C for 15 min. The super-
natants were decanted and frozen at −80°C until assayed.
sCD146 levels were assayed using CY-QUANT ELISA
sCD146 test kits (Biocytex, France). These assays are
based on a plastic support coated with specific mouse
monoclonal anti human CD146 F(ab’)2 fragments (Re-
agent 1), which bind to sCD146, and peroxidase-coupled
mouse monoclonal anti CD146 antibody (Reagent 5),
which binds to a remaining free antigenic determinant of
CD146. The bound peroxidase is reacted with TMB sub-
strate (Reagent 6) for a predetermined time. The reaction
is stopped (Reagent 8), and the intensity of the signal is
directly proportional to the sCD146 level of the original
sample, with sCD146 levels determined from standard
curves [30].Measurement of CIMT
CIMT in both diabetic and healthy individuals was eval-
uated by combined B-mode and color Doppler ultrason-
ography (Siemens, Germany), using a sectorial probe of
7.5 MHz with axial and lateral resolution of 0.15 mm.
CIMTs were measured using a predetermined, standard-
ized scanning protocol for the right and left carotid arter-
ies. The proximal part of the carotid bulb was identified
on both sides, and the segments of the common carotid
arteries 3 cm proximal to the bulb were scanned. Mea-
surements were performed on plaque-free segments by
the same expert under single-blind conditions. A segment
with an IMT >1.0 mm was defined as thickened, whereas
IMT ≤1.0 mm was considered normal.Table 1 Demographic characteristics, BMI and blood






(n = 37) (n = 37)
Mean (SD)
Age (years) 26.16 (4.07) 25.84 (3.05) 0.699
Gender (F/M) 23/14 21/16 0.636
Body mass
index (kg/m2)
22.43 (2.26) 21.41 (2.29) 0.057
Fasting plasma
glucose (mg/dL)
119.27 (27.40) 85.08 (7.33) 0.0001
HbA1c (%) 7.11 (0.9) 5.17 (0.25) 0.0001
Total cholesterol
(mg/dL)
163.54 (20.33) 161.08 (16.33) 0.568
LDL cholesterol (mg/dL) 86.95 (9.12) 82.11 (10.82) 0.041
HDL cholesterol (mg/dL) 53.00 (12.30) 54.19 (10.20) 0.652
Triglycerides (mg/dl) 66.11 (21.55) 68.59 (8.99) 0.519
Creatinine (mg/dl) 0.8 (0.3) 0.8 (0.2) 0.221
Values in bold indicate statistical significance (p<0.05).Statistical analysis
Calculation of group size showed that at least 37 pa-
tients per group were needed to detect a correlation co-
efficient of 0.46 between sCD146 and CIMT values in
patients with type I diabetes mellitus at a statistical power
(1 minus the β value) of 90% allowing for a type I (α) error
of 0.05.
All statistical analyses were performed using SPSS ver-
sion 15.0 software (SPSS Inc. Chicago, IL, USA). Cat-
egorical data were compared using chi-square (χ2) tests.
Student’s t tests and Mann Whitney U tests were used
to compare normally and non-normally distributed nu-
merical variables, respectively. Receiver operating char-
acteristic (ROC) curves for sCD146 and CMIT were
generated and the area under the curve (AUC) was cal-
culated to determine the cutoffs for each yielding opti-
mal sensitivity, specificity, positive predictive value
(PPV), negative predictive value (NPV) and likelihood
ratio (LR). Data were expressed as “mean (standard de-




measurements and blood biochemistry
Patients were determined to be diabetic for a mean (SD)
6.9 (3.3) years. Patient and control groups were similar
in mean (SD) age, mean (SD) BMI, and gender distribution.
Apart from significantly higher fasting plasma glucose
and HbA1c concentrations in patients than in controls
(p = 0.0001 each), there were no significant between group
differences in blood biochemistry (Table 1).
sCD146 and CIMT values
Mean (SD) sCD146 levels were significantly higher in pa-
tients with type 1 diabetes than in control subjects (314.6
(141.9) ng/ml vs. 207.8 (34.5) ng/ml, p = 0.001). In con-
trast, mean (SD) CIMT was similar in the patient and con-
trol groups (0.5 (0.1) mm vs. 0.4 (0.1) mm) (Table 2).
ROC curves for sCD146 and CMIT to differentiate type 1
diabetes mellitus from healthy controls
ROC analysis showed that an sCD146 level of
>260.74 ng/ml was the optimum cutoff for differentiating
individuals with type 1 diabetes mellitus and healthy con-
trols, with a sensitivity of 56.8%, a specificity of 94.6% and
an LR of 10.5%. ROC analysis also showed that the most
suitable cut-off value for CIMT was >0.5 mm, with a
sensitivity, specificity and LR of 56.8%, 54.1% and 1.24%,
respectively (Figure 1).
Table 2 sCD146 and CIMT values in the patient and
control groups
Type 1 diabetes Healthy controls p value
(n = 37) (n = 37)
Mean (SD)
sCD146 (ng/ml) 314.72 (139.88) 207.80 (34.51) 0.001
CIMT (mm) 0.48 (0.10) 0.44 (0.06) 0.153
CIMT Carotid artery intima-media thickness. Values in bold indicate statistical
significance (p<0.05).
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95% CI 0.613-0.826) for sCD146 and 0.588 (SE 0.066;
95% CI 0.468-0.870) for CIMT. ROC curves for sCD146
differed significantly in differentiating patients with type
1 diabetes from healthy controls (p = 0.0047) (Figure 1).
A significantly higher percentage of patients than of controls
had sCD146 levels >260 ng/ml (21/37 (56.8%) vs. 2/37
(5.4%), p = 0.00011).
Discussion
The present study assessing the relationship between
early atherosclerosis and endothelial dysfunction in type
1 diabetic patients showed that sCD146 levels were higherFigure 1 ROC curves for sCD146 and CMIT differentiating subjects wiin patients than in healthy controls, whereas CIMT values
did not differ in these two groups. An sCD146 concentra-
tion >260.74 ng/ml was 10.5-fold more likely in a subject
with type 1 diabetes than in a healthy control subject,
whereas a CIMT >0.5 mm was only 1.24-fold more likely
in a diabetic individual, suggesting that sCD146 is a better
predictor of early atherosclerosis than CIMT.
The greater ability of sCD146 than of CIMT in distin-
guishing between individuals with type 1 diabetes mellitus
and healthy controls in our study population appears
consistent with early vascular endothelial dysfunction and
atherosclerotic thickening being two different stages of
atherosclerosis [31,32]. Furthermore, CIMT and endothe-
lial dysfunction were not correlated in patients with early
stage diabetic retinopathy [31,32]. In contrast, sCD146
levels were correlated with the progression of diabetic
retinopathy, suggesting that sCD146 is associated with sig-
nificant endothelial damage [23,27]. Similarly, fluores-
cence microcopy showed that the number of CECs was
increased in subjects with type 2 diabetes [24,26], which is
not surprising since insulin resistance, hypertension,
hyperlipidemia and increased age may lead to endothelial
dysfunction. In addition, many of these patients received
medications that could affect endothelial cell function,th type 1 diabetes mellitus from healthy controls.
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clopidogrel [33].
Although increased sCD146 as a marker of increased
CECs predicting endothelial damage is an expected out-
come in type 2 diabetics, type 1 diabetes is a pure hormone
deficiency disease, providing a better basis for studying the
impact of hyperglycemia per se on mechanisms of vascular
injury. Thus, the increase in sCD146 levels in our popula-
tion of patients with uncomplicated type 1 diabetes, with
no additional cardiovascular risk factors, suggests that
hyperglycemia, and possibly hypoinsulinemia, may play
primary roles in the induction of endothelial damage. A
previous study in patients with type 1 diabetes without
concomitant disorders found an increased number of CECs
by fluorescence microscopy [25]. Those patients, however,
had a longer duration of diabetes than in our study, with
many of those patients having microvascular complica-
tions such as retinopathy, nephropathy and neuropathy.
Thus, the increase in sCD146 levels in those patients, rela-
tive to controls, was consistent with their concomitant
microvascular complications. In contrast, our patient
population did not have any diabetes related complica-
tions, including microalbuminuria, as well as having simi-
lar age, gender and lipid profiles as our healthy control
groups. Thus, the higher sCD146 levels in our patient
than in our control group may be a marker of early stage
complications in patients with type 1 diabetes.
Our finding, that CIMT values were similar in the type
1 diabetes and control groups, seems to contrast with
the results of The Epidemiology of Diabetes Intervention
and Complications (EDIC) Study, which reported that
CIMT was significantly higher in adults with type 1 than
type 2 diabetes of both sexes at 6 years of follow up,
suggesting the precocious development of atheroscler-
osis in patients with type 1 diabetes [34]. However, our
patients were younger and had a shorter duration of dia-
betes than patients in the EDIC Study. Moreover, none of
our patients had diabetes-related micro- and macrovascular
complications or additional cardiovascular risk factors.
Thus, our finding, that CIMT was similar in patients and
controls, was not surprising. Moreover, although CIMT
has been reported to be significantly higher in diabetic pa-
tients than in non-diabetic subjects, CIMT progression
was reported to be due not only to diabetes per se, but to
other concomitant metabolic abnormalities, in particular
arterial hypertension [14]. Thus, our failure to detect
diabetes-dependent changes in CIMT in our patients may
be due to their lack of diabetes-related complications and
additional cardiovascular risk factors.
Notably, mean CIMT level in our patients with type 1
diabetes was lower than in previous studies [35-40]. In
this regard, given the theory of the pathogenesis of ath-
erosclerosis [41], with detection of endothelial dysfunc-
tion predicting an early functional disturbance of thevessel wall and measurement of IMT functioning as an
early morphological sign [42], our findings emphasize
the likelihood that sCD146 is a more sensitive and earl-
ier predictor of subclinical endothelial dysfunction than
CIMT.
Likewise, endothelial dysfunction has been suggested
to be detected very early in the life of insulin resistant
subjects despite a lack of significant structural changes,
indicated by a thickening of the intima-media layer [16].
Consistent with our finding that, compared to CIMT,
sCD146 was better able to distinguish individuals with
type 1 diabetes mellitus from healthy controls, markers
of endothelial dysfunction have been regarded as more
helpful than measuring the thickness of the vascular wall
in identifying subjects at high risk for accelerated athero-
sclerosis at an early stage [16].
Conclusions
In conclusion, our findings showed that sCD146 but not
CIMT was significantly higher in a young population of
individuals with type 1 diabetes, with a relatively short
duration of diabetes and a lack of diabetes-related compli-
cations and additional cardiovascular risk factors, than in
matched healthy controls. Moreover, sCD146 was better
able to distinguish type 1 diabetes from healthy controls
than was CIMT. Our results suggest that sCD146 levels
may be a more sensitive marker than CIMT for the earlier
identification of type 1 diabetic patients at high risk for
atherosclerosis.
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